Colorectal Carcinoma (CRC), Gastric Cancer (GC), Pancreas Adenocarcinoma, Small Cell Lung Cancer (SCLC), Triple -Negative Breast Cancer
Conditions
Keywords
THE-0504, Solid tumors, Cancer, Single-centre, Thena Biotech, Italy, Phase 1, Europe
Brief summary
Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.
Detailed description
The primary aim of the Phase 1 study is to define the Recommended Phase 2 dose and the Maximum Tolerated Dose of THE-0504, as well as to assess the safety and tolerability of escalating doses of THE-0504 administered intravenously to patients with different types of solid tumors. The study will also provide first data in humans concerning safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of THE-0504. For the first-in-human study, a model based on a classic 3+3 design following a modified Fibonacci sequence for dose escalation will be implemented. THE-0504 will be administered IV on day 1 and day 8 of a 21-day cycle. At the end of 21 days from the first treatment of the first patient, the treatment of the second patient of the first Cohort will begin (according to the dose-escalation schedule of the specific Cohort). Intra-patient dose escalation will be permitted to minimize the chance of sub-optimal dosing. The results of the Phase 1 study will drive the future clinical development of THE-0504 in Phase 2 and Phase 3 studies.
Interventions
DRUGTHE-0504
THE-0504 will be administered intravenously according to the treatment regimen specified in the protocol.
Sponsors
Thena Biotech S.r.l.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients will be enrolled in the study if they meet all the following criteria: 1. written informed consent obtained; 2. both gender adult (≥ 18 years) patients; 3. diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa); 4. measurable metastatic disease or locally advanced unresectable tumors; 5. have exhausted all EMA-approved treatment options; 6. ECOG Performance Status graded as 0 or 1; 7. patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement; 8. adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment: * Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis). * Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor); 9. adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment: • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min per 1.73 m2 according to the CKD-EPI formula. 10. adequate bone marrow function as defined as: * Hgb ≥ 9 g/dL * ANC ≥1.5x109/L * PLT≥100.0 x109/L 11. Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.
Exclusion criteria
Patients will not be enrolled if they meet any of the following criteria: 1. pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women; 2. male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration; 3. additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy; 4. have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor; 5. ECOG Performance Status \> 2; 6. had not tolerated previously administered Top1 inhibitor treatments; 7. known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible); 8. serious concurrent illness; 9. Hgb \< 9 g/dL; 10. Transfusion dependent anemia with transfusion dependency of ≥3 months; 11. Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments; 12. Iron overload, hereditary hemochromatosis and similar; 13. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment; 14. Prolonged QTc interval; 15. Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease; 16. Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm; 17. History of severe allergic or anaphylactic reactions to previous protein-based therapy; 18. Currently receiving anticoagulation therapy with warfarin; 19. Known history of HIV infection, unless all the following are applicable: * receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention; * CD4 T-cell count \> 350 cells/μL * CD4 T-cell nadir (lowest historical count) \> 350 cells/μL, and • viral load confirmed as \< 50 copies/mL. 20. HBV infection, unless on stable anti-viral therapy for \> 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable; 21. Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease; 22. Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension; 23. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations; 24. History of drugs and/or alcohol abuse; 25. Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and/or surgical procedures or other medical or ethical reasons); 26. Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups; 27. Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs/products up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs/products under investigation\*\*); or previous participation in the same trial or planned to receive other investigational products during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of Maximum Tolerated Dose (MTD) | From enrollment to completion of Cycle 1 (each cycle is 21 days) |
| Assessment of Recommended Phase 2 Dose (RP2D) | During dose escalation, at the end of cycle 1 (each cycle is 21 days) |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic assessments of the IMP | Pre-dose and up to 96 hours (30 minutes, 3 hours, 24 hours, 48 hours and 96 hours) post-dose of the first 3 Cycles (63 days) |
| Uprising / incidence of anti-THE-05 antibodies (ADA) | From baseline through Cycle 4 (84 days) |
| Objective Response Rate (ORR) according to RECIST 1.1 | From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months) |
| Progression-Free Survival (PFS) | From enrollment until disease progression or death from any cause (assessed up to 36 months) |
| Overall Survival (OS) | From first IMP administration until death from any cause (assessed up to 36 months) |
| Rate of patients with Complete Response (CR) or Partial Response (PR) according to RECIST 1.1 | From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months) |
| Assessment of safety profile of the product THE-0504 | From first IMP administration through 90 days after last IMP administration |
| ECOG Performance Status changes from baseline | From baseline through 90 days after last IMP administration |
Countries
Italy
Contacts
CONTACTPierpaolo Ceci, PhD
CONTACTGennaro Daniele, PhD
PRINCIPAL_INVESTIGATORGennaro Daniele
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Outcome results
None listed